Exfoliation syndrome: New genetic and pathophysiologic insights

Current Opinion in Ophthalmology

Volumn 24, Issue 2, 2013, Pages 167-174

  Seina, Julia ^a   Galora, Anat ^a,b   Shetha, Anoop ^a   Kruha, Jonathan ^a   Pasqualec, Louis R ^c   Karpa, Carol L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clinical Manifestations; Exfoliation Syndrome; Genetics; Oxidative Stress; Pathophysiology

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; AMYLOID; APOLIPOPROTEIN E; CLUSTERIN; CONTACTIN; ELASTIN; ENTACTIN; FIBRILLIN 1; FIBRONECTIN; GELATINASE A; HOMOCYSTEINE; LAMININ; PROTEIN LYSINE 6 OXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; TROPOELASTIN; VITRONECTIN;

AUTOSOMAL DOMINANT INHERITANCE; CATARACTOGENESIS; CENTRAL RETINA VEIN OCCLUSION; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; FIBER; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEREDITY; HUMAN; INTRAOCULAR PRESSURE; OPEN ANGLE GLAUCOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; PSEUDOEXFOLIATION; RADIATION EXPOSURE; REGULATOR GENE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ULTRAVIOLET RADIATION; VISUAL ACUITY;

EXFOLIATION SYNDROME; HUMANS; OXIDATIVE STRESS;

EID: 84876280777     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32835d5d11     Document Type: Review

References (79)

1. Lindberg JG. Clinical investigations on depigmentation of the pupillary border and translucency of the iris in cases of senile cataract and in normal eyes in elderly persons. Acta Ophthalmol Suppl 1989; 190:1-96.
2. Lemmela S, Forsman E, Onkamo P, et al. Association of LOXL1 gene with Finnish exfoliation syndrome patients. J Hum Genet 2009; 54:289-297.
3. Malukiewicz G, Lesiewska-Junk H, Linkowska K, et al. Analysis of LOXL1 single nucleotide polymorphisms in Polish population with pseudoexfoliation syndrome. Acta Ophthalmol 2011; 89:e64-e66.
4. Shazly TA, Farrag AN, Kamel A, Al-Hussaini AK. Prevalence of pseudoexfoliation syndrome and pseudoexfoliation glaucoma in Upper Egypt. BMC Ophthalmol 2011; 11:18.
5. Kang JH, Loomis S, Wiggs JL, et al. Demographic and geographic features of exfoliation glaucoma in 2 United States-based prospective cohorts. Ophthalmology 2012; 119:27-35. This prospective cohort study of over 100 000 men and women without ES or exfoliation glaucoma (ESG) at baseline in the USA identified increasing age, female sex as well as living in more northern regions as significant risk factors for developing ES.
6. Stein JD, Pasquale LR, Talwar N, et al. Geographic and climatic factors associated with exfoliation syndrome. Arch Ophthalmol 2011; 129:1053-1060.
7. Forsman E, Cantor RM, Lu A, et al. Exfoliation syndrome: prevalence and inheritance in a subisolate of the Finnish population. Acta Ophthalmol Scand 2007; 85:500-507.
8. Orr AC, Robitaille JM, Price PA, et al. Exfoliation syndrome: clinical and genetic features. Ophthalmic Genet 2001; 22:171-185.
9. Abu-Amero KK, Cabrera VM, Larruga JM, et al. Eurasian and Sub-Saharan African mitochondrial DNA haplogroup influences pseudoexfoliation glaucoma development in Saudi patients. Mol Vis 2011; 17:543-547.
10. Schlotzer-Schrehardt U, Pasutto F, Sommer P, et al. Genotype-correlated expression of lysyl oxidase-like 1 in ocular tissues of patients with pseudoexfoliation syndrome/glaucoma and normal patients. Am J Pathol 2008; 173:1724-1735.
11. Lee RK. The molecular pathophysiology of pseudoexfoliation glaucoma. Curr Opin Ophthalmol 2008; 19:95-101.
12. Thorleifsson G, Magnusson KP, Sulem P, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science 2007; 317:1397-1400.
13. Challa P. Genetics of pseudoexfoliation syndrome. Curr Opin Ophthalmol 2009; 20:88-91.
14. Wiggs JL. Association Between LOXL1 and pseudoexfoliation. Arch Ophthalmol 2008; 126:420-421.
15. Schlotzer-Schrehardt U. [New pathogenetic insights into pseudoexfoliation syndrome/glaucoma. Therapeutically relevant?]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2012; 109:944-951.
16. Ramprasad VL, George R, Soumittra N, et al. Association of nonsynonymous single nucleotide polymorphisms in the LOXL1 gene with pseudoexfoliation syndrome in India. Mol Vis 2008; 14:318-322.
17. Micheal S, Khan MI, Akhtar F, et al. Role of Lysyl oxidase-like 1 gene polymorphisms in Pakistani patients with pseudoexfoliative glaucoma. Mol Vis 2012; 18:1040-1044.
18. Ozaki M, Lee KY, Vithana EN, et al. Association of LOXL1 gene polymorphisms with pseudoexfoliation in the Japanese. Invest Ophthalmol Vis Sci 2008; 49:3976-3980.
19. Chen L, Jia L, Wang N, et al. Evaluation of LOXL1 polymorphisms in exfoliation syndrome in a Chinese population. Mol Vis 2009; 15:2349-2357.
20. Fan BJ, Pasquale LR, Rhee D, et al. LOXL1 promoter haplotypes are associated with exfoliation syndrome in a U.S. Caucasian population. Invest Ophthalmol Vis Sci 2011; 52:2372-2378.
21. Chen H, Chen LJ, Zhang M, et al. Ethnicity-based subgroup meta-analysis of the association of LOXL1 polymorphisms with glaucoma. Mol Vis 2010; 16:167-177.
22. Jaimes M, Rivera-Parra D, Miranda-Duarte A, et al. Prevalence of high-risk alleles in the LOXL1 gene and its association with pseudoexfoliation syndrome and exfoliation glaucoma in a Latin American population. Ophthalmic Genet 2012; 33:12-17.
23. Malukiewicz G, Lesiewska-Junk H, Linkowska K, et al. Analysis of CNTNAP2 polymorphisms in Polish population with pseudoexfoliation syndrome. Acta Ophthalmol 2012; 90:e660-e661.
24. Krumbiegel M, Pasutto F, Schlotzer-Schrehardt U, et al. Genome-wide association study with DNA pooling identifies variants at CNTNAP2 associated with pseudoexfoliation syndrome. Eur J Hum Genet 2011; 19:186-193.
25. Schlotzer-Schrehardt U. Genetics and genomics of pseudoexfoliation syndrome/glaucoma. Middle East Afr J Ophthalmol 2011; 18:30-36. A review of the genetics and nongenetic factors involved in the pathogenesis of ES LOXL1 identified as a major risk factor for development of ES and ESG. Other genes such as clusterin, CNTNAP2, APOE, glutathione S-transferases, and TNF-a and nongenetic factors such as oxidative stress and various growth factors additionally noted to play a role.
26. Krumbiegel M, Pasutto F, Mardin CY, et al. Exploring functional candidate genes for genetic association in german patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci 2009; 50:2796-2801.
27. Zenkel M, Kruse FE, Junemann AG, et al. Clusterin deficiency in eyes with pseudoexfoliation syndrome may be implicated in the aggregation and deposition of pseudoexfoliative material. Invest Ophthalmol Vis Sci 2006; 47:1982-1990.
28. Naumann GO, Schlotzer-Schrehardt U. Keratopathy in pseudoexfoliation syndrome as a cause of corneal endothelial decompensation: a clinicopathologic study. Ophthalmology 2000; 107:1111-1124.
29. Damji KF, Bains HS, Stefansson E, et al. Is pseudoexfoliation syndrome inheritedA review of genetic and nongenetic factors and a new observation. Ophthalmic Genet 1998; 19:175-185.
30. Taylor HR. Pseudoexfoliation, an environmental diseaseTrans Ophthalmol Soc U K 1979; 99:302-307.
31. Yilmaz A, Ayaz L, Tamer L. Selenium and pseudoexfoliation syndrome. Am J Ophthalmol 2011; 151:272-276.
32. Pasquale LR, Wiggs JL, Willett WC, Kang JH. The relationship between caffeine and coffee consumption and exfoliation glaucoma or glaucoma suspect: a prospective study in two cohorts. Invest Ophthalmol Vis Sci 2012; 53:6427-6433.
33. Schlotzer-Schrehardt U, Naumann GO. Ocular and systemic pseudoexfoliation syndrome. Am J Ophthalmol 2006; 141:921-937.
34. Ovodenko B, Rostagno A, Neubert TA, et al. Proteomic analysis of exfoliation deposits. Invest Ophthalmol Vis Sci 2007; 48:1447-1457.
35. Sharma S, Chataway T, Burdon KP, et al. Identification of LOXL1 protein and apolipoprotein E as components of surgically isolated pseudoexfoliation material by direct mass spectrometry. Exp Eye Res 2009; 89:479-485.
36. Krumbiegel M, Pasutto F, Mardin CY, et al. Apolipoprotein E genotypes in pseudoexfoliation syndrome and pseudoexfoliation glaucoma. J Glaucoma 2010; 19:561-565.
37. Abu-Amero KK, Kondkar AA, Mousa A, et al. Decreased total antioxidants status in the plasma of patients with pseudoexfoliation glaucoma. Mol Vis 2011; 17:2769-2775. This study evaluated the total antioxidant status in the plasma of pseudoexfoliation glaucoma using spectrophotometric and enzyme-linked immunosorbent assay and found there was significantly decreased total oxidative state (TAS) in PEXG patients. It is also the first study in which combined effect of the TAS and the LOXL1 SNPs on the G allele (rs1048661 and rs3825942) was investigated.
38. Koliakos GG, Konstas AG, Schlotzer-Schrehardt U, et al. 8-Isoprostaglandin F2a and ascorbic acid concentration in the aqueous humour of patients with exfoliation syndrome. Br J Ophthalmol 2003; 87:353-356.
39. Koliakos GG, Befani CD, Mikropoulos D, et al. Prooxidant-antioxidant balance, peroxide and catalase activity in the aqueous humour and serum of patients with exfoliation syndrome or exfoliative glaucoma. Graefes Arch Clin Exp Ophthalmol 2008; 246:1477-1483.
40. Gartaganis SP, Patsoukis NE, Nikolopoulos DK, Georgiou CD. Evidence for oxidative stress in lens epithelial cells in pseudoexfoliation syndrome. Eye (Lond) 2007; 21:1406-1411.
41. Ucakhan OO, Karel F, Kanpolat A, et al. Superoxide dismutase activity in the lens capsule of patients with pseudoexfoliation syndrome and cataract. J Cataract Refract Surg 2006; 32:618-622.
42. Zenkel M, Kruse FE, Naumann GO, Schlotzer-Schrehardt U. Impaired cytoprotective mechanisms in eyes with pseudoexfoliation syndrome/glaucoma. Invest Ophthalmol Vis Sci 2007; 48:5558-5566.
43. Browne JG, Ho SL, Kane R, et al. Connective tissue growth factor is increased in pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci 2011; 52:3660-3666.
44. Takai Y, Tanito M, Ohira A. Multiplex cytokine analysis of aqueous humor in eyes with primary open-angle glaucoma, exfoliation glaucoma, and cataract. Invest Ophthalmol Vis Sci 2012; 53:241-247.
45. Djordjevic-Jocic J, Zlatanovic G, Veselinovic D, et al. Transforming growth factor beta1, matrix-metalloproteinase-2 and its tissue inhibitor in patients with pseudoexfoliation glaucoma/syndrome. Vojnosanit Pregl 2012; 69:231-236.
46. Schlotzer-Schrehardt U, Lommatzsch J, Kuchle M, et al. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2003; 44:1117-1125.
47. Maatta M, Tervahartiala T, Harju M, et al. Matrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma, exfoliation syndrome, and exfoliation glaucoma. J Glaucoma 2005; 14:64-69.
48. Roedl JB, Bleich S, Reulbach U, et al. Homocysteine in tear fluid of patients with pseudoexfoliation glaucoma. J Glaucoma 2007; 16:234-239.
49. Xu F, Zhang L, Li M. Plasma homocysteine, serum folic acid, serum vitamin B12, serum vitamin B6, MTHFR and risk of pseudoexfoliation glaucoma: a meta-analysis. Graefes Arch Clin Exp Ophthalmol 2012; 250:1067-1074. A prospective observational case series of 12 patients with unilateral clinical pseudoexfoliation determining the efficacy of nonfocal laser microscopy in detecting clinical changes in ES. This new technology which visualizes changes in cornea and lens of unaffected eyes in unilateral ES may play an important diagnostic role in the future.
50. Kivela T, Hietanen J, Uusitalo M. Autopsy analysis of clinically unilateral exfoliation syndrome. Invest Ophthalmol Vis Sci 1997; 38:2008-2015.
51. Sbeity Z, Palmiero PM, Tello C, et al. Noncontact in-vivo confocal scanning laser microscopy in exfoliation syndrome, exfoliation syndrome suspect and normal eyes. Acta Ophthalmol 2011; 89:241-247.
52. Erdogan H, Arici DS, Toker MI, et al. Conjunctival impression cytology in pseudoexfoliative glaucoma and pseudoexfoliation syndrome. Clin Experiment Ophthalmol 2006; 34:108-113.
53. Oliveira C, Schlotzer-Schrehardt U, Vieira G, et al. Early diagnosis of exfoliation syndrome in the offspring of affected patients. Acta Ophthalmol Scand 2006; 84:512-515.
54. Zheng X, Shiraishi A,Okuma S, et al. In-vivo confocal microscopic evidence of keratopathy in patients with pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci 2011; 52:1755-1761.
55. Yenerel NM, Gorgun E, Kucumen RB, et al. Corneal biomechanical properties of patients with pseudoexfoliation syndrome. Cornea 2011; 30:983-986.
56. Cankaya AB, Anayol A, Ozcelik D, et al. Ocular response analyzer to assess corneal biomechanical properties in exfoliation syndrome and exfoliative glaucoma. Graefes Arch Clin Exp Ophthalmol 2012; 250:255-260.
57. Ayala M. Corneal hysteresis in normal subjects and in patients with primary open-angle glaucoma and pseudoexfoliation glaucoma. Ophthalmic Res 2011; 46:187-191. This study identified significantly decreased corneal hysteresis in ESG patients in comparison to primary open-angle glaucoma and control patients.
58. Ritch R, Schlotzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol 2001; 45:265-315.
59. Shuba L, Nicolela MT, Rafuse PE. Correlation of capsular pseudoexfoliation material and iridocorneal angle pigment with the severity of pseudoexfoliation glaucoma. J Glaucoma 2007; 16:94-97.
60. Schlotzer-Schrehardt U, Naumann GO. Trabecular meshwork in pseudoexfoliation syndrome with and without open-angle glaucoma. A morphometric, ultrastructural study. Invest Ophthalmol Vis Sci 1995; 36:1750-1764.
61. Gottanka J, Flugel-Koch C, Martus P, et al. Correlation of pseudoexfoliative material and optic nerve damage in pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci 1997; 38:2435-2446.
62. Johnson TV, Fan S, Camras CB, Toris CB. Aqueous humor dynamics in exfoliation syndrome. Arch Ophthalmol 2008; 126:914-920.
63. Yarangumeli A, Davutluoglu B, Koz OG, et al. Glaucomatous damage in normotensive fellow eyes of patients with unilateral hypertensive pseudoexfoliation glaucoma: normotensive pseudoexfoliation glaucomaClin Experiment Ophthalmol 2006; 34:15-19.
64. Koz OG, Turkcu MF, Yarangumeli A, et al. Normotensive glaucoma and risk factors in normotensive eyes with pseudoexfoliation syndrome. J Glaucoma 2009; 18:684-688.
65. Schlotzer-Schrehardt U, Hammer CM, Krysta AW, et al. LOXL1 Deficiency in the lamina cribrosa as candidate susceptibility factor for a pseudoexfoliationspecific risk of glaucoma. Ophthalmology 2012; 119:1832-1843. An observational consecutive case series that suggested the possible impact of LOX1 dysregulation on the elastinopathy of lamina cribrosa and pressure-induced optic neuropathy and glaucoma development in ES syndrome.
66. Braunsmann C, Hammer CM, Rheinlaender J, et al. Evaluation of lamina cribrosa and peripapillary sclera stiffness in pseudoexfoliation and normal eyes by atomic force microscopy. Invest Ophthalmol Vis Sci 2012; 53:2960-2967.
67. Puska P, Tarkkanen A. Exfoliation syndrome as a risk factor for cataract development: five-year follow-up of lens opacities in exfoliation syndrome. J Cataract Refract Surg 2001; 27:1992-1998.
68. Kanthan GL, Mitchell P, Burlutsky G, et al. Pseudoexfoliation syndrome and the long-term incidence of cataract and cataract surgery: the blue mountains eye study. Am J Ophthalmol 2013; 155:83-88, e81.
69. Dayanir V, Topaloglu A, Ozsunar Y, et al. Orbital blood flow parameters in unilateral pseudoexfoliation syndrome. Int Ophthalmol 2009; 29: 27-32.
70. Ritch R, Prata TS, de Moraes CG, et al. Association of exfoliation syndrome and central retinal vein occlusion: an ultrastructural analysis. Acta Ophthalmol 2010; 88:91-95.
71. Cursiefen C, Hammer T, Kuchle M, et al. Pseudoexfoliation syndrome in eyes with ischemic central retinal vein occlusion. A histopathologic and electron microscopic study. Acta Ophthalmol Scand 2001; 79:476-478.
72. Prata TS, Rozenbaum I, de Moraes CG, et al. Retinal vascular occlusions occur more frequently in the more affected eye in exfoliation syndrome. Eye (Lond) 2010; 24:658-662.
73. Gillies WE, Brooks AM. Central retinal vein occlusion in pseudoexfoliation of the lens capsule. Clin Experiment Ophthalmol 2002; 30:176-187.
74. Amari F, Umihira J, Nohara M, et al. Electron microscopic immunohistochemistry of ocular and extraocular pseudoexfoliative material. Exp Eye Res 1997; 65:51-56.
75. Djordjevic-Jocic J, Jovanovic P, Bozic M, et al. Prevalence and early detection of abdominal aortic aneurysm in pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Curr Eye Res 2012; 37:617-623.
76. Linner E, Popovic V, Gottfries CG, et al. The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type. Acta Ophthalmol Scand 2001; 79:283-285.
77. Citirik M, Acaroglu G, Batman C, et al. A possible link between the pseudoexfoliation syndrome and coronary artery disease. Eye (Lond) 2007; 21:11-15.
78. Ringvold A, Blika S, Sandvik L. Pseudo-exfoliation and mortality. Acta Ophthalmol Scand 1997; 75:255-256.
79. Shrum KR, Hattenhauer MG, Hodge D. Cardiovascular and cerebrovascular mortality associated with ocular pseudoexfoliation. Am J Ophthalmol 2000; 129:83-86.